LambdaVision and the frontier of space-enabled biomanufacturing
At the intersection of biotechnology and space manufacturing, LambdaVision recently closed a $7 million seed funding round to accelerate development and space-based manufacturing of its protein-based artificial retina. This injection of capital, led by Seven Seven Six and Aurelia Foundry Fund, with participation from Seraphim Space, extends the company’s operational runway into 2027 and underpins plans to scale production of next-generation vision-restoring implants in low Earth orbit.
Expand Expanding Close